166 related articles for article (PubMed ID: 28463406)
1. CPT11 prevents virus replication in JCI cells persistently infected with JC polyomavirus.
Nukuzuma S; Nukuzuma C; Kameoka M; Sugiura S; Nakamichi K; Tasaki T; Takegami T
Microbiol Immunol; 2017 Jun; 61(6):232-238. PubMed ID: 28463406
[TBL] [Abstract][Full Text] [Related]
2. Suppressive effect of topoisomerase inhibitors on JC polyomavirus propagation in human neuroblastoma cells.
Nukuzuma S; Nakamichi K; Kameoka M; Sugiura S; Nukuzuma C; Tasaki T; Takegami T
Microbiol Immunol; 2016 Apr; 60(4):253-60. PubMed ID: 26935240
[TBL] [Abstract][Full Text] [Related]
3. Establishment of COS-JC cells persistently producing archetype JC polyomavirus.
Nukuzuma S; Nukuzuma C; Kameoka M; Sugiura S; Nakamichi K; Tasaki T; Hidaka K; Takegami T
Microbiol Immunol; 2018 Aug; 62(8):524-530. PubMed ID: 29932215
[TBL] [Abstract][Full Text] [Related]
4. Human iPS cell-derived astrocytes support efficient replication of progressive multifocal leukoencephalopathy-type JC polyomavirus.
Shimbo E; Nukuzuma S; Tagawa YI
Biochem Biophys Res Commun; 2020 Dec; 533(4):983-987. PubMed ID: 33008586
[TBL] [Abstract][Full Text] [Related]
5. High expression of JC polyomavirus-encoded microRNAs in progressive multifocal leukoencephalopathy tissues and its repressive role in virus replication.
Takahashi K; Sato Y; Sekizuka T; Kuroda M; Suzuki T; Hasegawa H; Katano H
PLoS Pathog; 2020 Apr; 16(4):e1008523. PubMed ID: 32324824
[TBL] [Abstract][Full Text] [Related]
6. Antiviral effects of artesunate on JC polyomavirus replication in COS-7 cells.
Sharma BN; Marschall M; Rinaldo CH
Antimicrob Agents Chemother; 2014 Nov; 58(11):6724-34. PubMed ID: 25155602
[TBL] [Abstract][Full Text] [Related]
7. Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy.
Ngouth N; Monaco MC; Walker L; Corey S; Ikpeama I; Fahle G; Cortese I; Das S; Jacobson S
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746716
[TBL] [Abstract][Full Text] [Related]
8. Characterization of JC Polyomavirus Derived from COS-IMRb Cells.
Nukuzuma S; Nukuzuma C; Kameoka M; Sugiura S; Nakamichi K; Tasaki T; Hidaka K; Takegami T
Jpn J Infect Dis; 2021 Jan; 74(1):48-53. PubMed ID: 32741932
[TBL] [Abstract][Full Text] [Related]
9. ERK Is a Critical Regulator of JC Polyomavirus Infection.
DuShane JK; Wilczek MP; Mayberry CL; Maginnis MS
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321332
[TBL] [Abstract][Full Text] [Related]
10. Progressive multifocal leukoencephalopathy-associated mutations in the JC polyomavirus capsid disrupt lactoseries tetrasaccharide c binding.
Maginnis MS; Ströh LJ; Gee GV; O'Hara BA; Derdowski A; Stehle T; Atwood WJ
mBio; 2013 Jun; 4(3):e00247-13. PubMed ID: 23760462
[TBL] [Abstract][Full Text] [Related]
11. Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.
Jelcic I; Combaluzier B; Jelcic I; Faigle W; Senn L; Reinhart BJ; Ströh L; Nitsch RM; Stehle T; Sospedra M; Grimm J; Martin R
Sci Transl Med; 2015 Sep; 7(306):306ra150. PubMed ID: 26400911
[TBL] [Abstract][Full Text] [Related]
12. The human JC polyomavirus (JCPyV): virological background and clinical implications.
Hirsch HH; Kardas P; Kranz D; Leboeuf C
APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
[TBL] [Abstract][Full Text] [Related]
13. Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment.
Prezioso C; Grimaldi A; Landi D; Nicoletti CG; Brazzini G; Piacentini F; Passerini S; Limongi D; Ciotti M; Palamara AT; Marfia GA; Pietropaolo V
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578264
[TBL] [Abstract][Full Text] [Related]
14. JC Polyomavirus Infection Reveals Delayed Progression of the Infectious Cycle in Normal Human Astrocytes.
Wilczek MP; DuShane JK; Armstrong FJ; Maginnis MS
J Virol; 2020 Feb; 94(5):. PubMed ID: 31826993
[TBL] [Abstract][Full Text] [Related]
15. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
Prezioso C; Zingaropoli MA; Iannetta M; Rodio DM; Altieri M; Conte A; Vullo V; Ciardi MR; Palamara AT; Pietropaolo V
Mult Scler Relat Disord; 2020 Jun; 41():102008. PubMed ID: 32087593
[TBL] [Abstract][Full Text] [Related]
16. Understanding polyomavirus CNS disease - a perspective from mouse models.
Ayers KN; Carey SN; Lukacher AE
FEBS J; 2022 Oct; 289(19):5744-5761. PubMed ID: 34145975
[TBL] [Abstract][Full Text] [Related]
17. Utility of droplet digital PCR for the quantitative detection of polyomavirus JC in clinical samples.
Giovannelli I; Ciccone N; Vaggelli G; Malva ND; Torricelli F; Rossolini GM; Giannecchini S
J Clin Virol; 2016 Sep; 82():70-75. PubMed ID: 27454232
[TBL] [Abstract][Full Text] [Related]
18. Teriflunomide Inhibits JCPyV Infection and Spread in Glial Cells and Choroid Plexus Epithelial Cells.
O'Hara BA; Gee GV; Haley SA; Morris-Love J; Nyblade C; Nieves C; Hanson BA; Dang X; Turner TJ; Chavin JM; Lublin A; Koralnik IJ; Atwood WJ
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575975
[TBL] [Abstract][Full Text] [Related]
19. IFNα and β Mediated JCPyV Suppression through C/EBPβ-LIP Isoform.
May D; Bellizzi A; Kassa W; Cipriaso JM; Caocci M; Wollebo HS
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696366
[TBL] [Abstract][Full Text] [Related]
20. Archetype JC polyomavirus DNA associated with extracellular vesicles circulates in human plasma samples.
Scribano S; Guerrini M; Arvia R; Guasti D; Nardini P; Romagnoli P; Giannecchini S
J Clin Virol; 2020 Jul; 128():104435. PubMed ID: 32442760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
